-
PAH therapy Uptravi recommended for use through Scotland’s NHS
Scottish patients with pulmonary arterial hypertension (PAH) can now be treated with Actelion‘s Uptravi (selexipag) through the country’s National Health System (NHS) after a positive recommendation from the Scottish Medicines Consortium (SMC). However, the use of this therapy will be restricted to adult patients in WHO functional class 3 whose symptoms are not manageable or do not tolerate other available PAH therapies.
Read more about this story here: Scottish Agency Recommends Uptravi for PAH Treatment Through National Health System
Have you heard of selexipag? What do you think of this news?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.